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Abstract
Debate is around the optimal immunization regimen for cancer vaccines since too intense vaccination schedules may exhaust 
reactive lymphocytes. GX301 is a telomerase-based cancer vaccine whose safety and immunological effects were tested in a 
phase I trial applying an eight administrations schedule. Main objective of this study was to comparatively analyse safety and 
immunological response to three GX301 regimens in metastatic castration-resistant prostate cancer patients with response/
disease stability after docetaxel chemotherapy. This was a multicentre, randomized, parallel-group, open-label trial registered 
with EudraCT (2014-000095-26) and ClinicalTrials.gov (NCT02293707, 2014). Ninety-eight patients were randomized 
to receive either eight (regimen 1), four (regimen 2) or two (regimen 3) vaccine administrations. Sixty-three patients were 
assessable for the primary immunological end-point. Vaccine-specific immune responses were evaluated by intracellular 
staining for IFN, elispot and cytotoxic assay at 90 and 180 days from baseline. No major side effects were recorded. A 54% 
overall immune responder rate was observed with 95% of patients showing at least one vaccine-specific immune response. 
Rate of immunological responders and number of immunizations were proportionally related, suggesting superiority of 
regimens 1 and 2 over regimen 3. Overall survival did not differ among regimens in both immunological responders and 
non-responders and was inversely associated (P = 0.002) with increase in the number of circulating CD8 + T regulatory 
cells at 180 days. These data indicate that GX301 cancer vaccine is safe and immunogenic in metastatic castration-resistant 
prostate cancer patients. Schedules with high number of administrations should be preferred in future studies due to their 
better immunological outcome.
Keywords GX301 cancer vaccine · Telomerase · Prostate cancer · Cancer vaccine schedule · CD8 + T regulatory 
lymphocytes
Introduction
Prostate cancer (PC) is the most common cancer and a lead-
ing cause of death from cancer in men [1]. Most of the PC 
patients with metastatic disease are responsive to andro-
gen deprivation for a limited time and eventually develop 
castration-resistant disease [2]. Metastatic castration-resist-
ant PC (mCRPC) represents a lethal condition for the great 
majority of patients, though notable changes occurred in 
the last 15 years. In 2004, docetaxel was the first drug to 
demonstrate an overall survival (OS) benefit in mCRPC [3], 
and in 2010, a comparable advantage was demonstrated for 
cabazitaxel in patients progressing on docetaxel [4]. Subse-
quently, abiraterone acetate and enzalutamide were approved 
for mCRPC in the post-docetaxel [5, 6] and later on in the 
pre-docetaxel setting [7, 8].
While the introduction of these novel therapies improved 
the prognosis of mCRPC to a measurable extent in single trials 
[4–8], their real-life impact is moderate [9–11]. Therefore, new 
approaches are urgently needed to improve the prognosis of 
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metastatic PC patients, especially when androgen deprivation 
resistance develops.
PC is potentially an immunogenic tumour [12] so that it 
could benefit from immuno-stimulating treatments. Several 
vaccination protocols are under evaluation as anti-cancer 
therapies [13–15] and sipuleucel-T received FDA and EMA 
approvals as treatment for PC [16].
Telomerase, the reverse transcriptase responsible for the 
synthesis, elongation and stability of the telomeric regions of 
chromosomes [17–20], which is normally expressed by embry-
onic cells but not by adult somatic cells with a few excep-
tions, is re-expressed by tumour cells, including PC cells, since 
essential for tumour immortalization [21–25].
Telomerase is immunogenic, and telomerase-specific 
T cells were identified in both healthy subjects and cancer 
patients [26–28], so that telomerase has been proposed as a 
universal tumour-associated antigen [29].
GX301 is a new telomerase-based cancer vaccine com-
posed of four immunogenic peptides from human telomerase 
and two complementary adjuvants. The immunogenicity of 
GX301 was demonstrated in an ex vivo study in which circu-
lating T cell responses to its hTERT peptides were detected 
in all (100%) of 21 tested subjects [30]. This implies that the 
four GX301 peptides endow a cumulative epitope pattern 
wide enough for escaping processes of central tolerance and 
for inducing telomerase-specific peripheral T cell reactivity 
in most individuals. A phase I first-in-humans trial, aimed 
at assessing the safety and immunological effects of GX301 
in patients with mCRPC or stage IV renal cancer resistant 
to conventional treatments, showed evidence of vaccine-
specific immunological responses in all patients [31]. In this 
trial, a fixed vaccination regimen was used, consisting of eight 
GX301 administrations over a period of 9 weeks [31].
Determining optimal immunization regimens for cancer 
vaccines is still a problematic issue. Some observations sug-
gest that repeated boosts may exhaust central memory T lym-
phocytes, which continuously re-populate the compartment of 
vaccine-specific memory cells [32]. Hence, a too intense vac-
cination schedule might lead to loss of late immune responses 
and shortened vaccine efficacy.
We report here the results of a Phase II randomized clinical 
trial whose main objectives were to compare the immunologi-
cal response to three GX301 regimens and to extend Phase 
I findings on GX301 safety in a larger sample of mCRPC 




This was a multicentre, randomized, parallel-group, open-
label trial with blind assessment of the primary end-point. 
The study was carried out in compliance with the Helsinki 
Declaration. The protocol was approved by national com-
petent authorities (AIFA and AEMPS, respectively) and the 
ethics committees of all participating hospitals and was reg-
istered with EudraCT (2014-000095-26) and ClinicalTrials.
gov (NCT02293707). All patients were required to sign a 
written informed consent before enrolling into the study.
The primary end-points were safety assessment and eval-
uation of immunological response defined as the achieve-
ment of an immunological score ≥ 3 (see below). Analysis 
of clinical efficacy was a secondary end-point.
Main eligibility criteria were (a) previously histologi-
cally confirmed diagnosis of m CRPC; (b) documented 
achievement of response or disease stability after docetaxel 
chemotherapy.
Treatments
GX301 vaccine is composed of four hTERT peptides (pep-
tides 540–548, 611–626, 672–686, 766–780) and two adju-
vants, Montanide ISA-51 VG and imiquimod. Each hTERT 
peptide was supplied as 625 µg lyophilised powder vials by 
Bachem AG, Bubendorf, Switzerland. Montanide was sup-
plied as 3 mL vials by Seppic SA, La Garenne Colombes, 
France. Imiquimod is a medicinal product marketed as sin-
gle-dose sachets containing 12.5 mg imiquimod as 5% cream 
(Meda Pharma SpA, Milan, Italy).
Each GX301 administration consisted of four intrader-
mal injections (one for each peptide) given in the abdominal 
region and followed by topical application of imiquimod. 
Each intradermal injection consisted of a fixed hTERT 
peptide dose, 500 μg, reconstituted as a saline solution and 
mixed with Montanide (1:1) using a standardized dispos-
able device.
The three GX301 regimens consisted of either eight 
administrations (Regimen 1) on days 1, 3, 5, 7, 14, 21, 35 
and 63, four administrations (Regimen 2) on days 1, 14, 
35 and 63, or two administrations (Regimen 3) on days 
1 and 63 (Supplementary Table 1). Day 1 was the day of 
randomization.
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Safety assessments
Treatment-emergent adverse events (AEs) were recorded 
throughout on-study observation. AEs were graded for 
severity according to Common Terminology Criteria for 
Adverse Events (CTCAE), version 4.0. AEs that were fatal, 
life-threatening or requiring/prolonging hospitalization, 
resulting in significant disability, or otherwise judged as 
medically important events, were classified as serious.
Immunological response assessment
Assessment of the immunological efficacy of GX301 
regimens was based on the following tests performed on 
peripheral blood mononuclear cells (PBMC): (1) Peptide-
specific ELISPOT assay for the evaluation of frequency of 
IFNγ–secreting T lymphocytes; (2) Peptide-specific intra-
cellular staining and flow cytometry analysis for evaluation 
of the frequency of circulating IFNγ–secreting CD4 + and 
CD8 + T lymphocytes; (3) Peptide-specific cytotoxic assay.
Blood samples for immunological testing were taken 
at baseline (randomization), day 90 and day 180. Positive 
test responses found on days 90 and 180 were considered 
vaccine-related if they were either new (i.e. not detected at 
baseline) or greater than twice the baseline value. Individual 
immunological outcomes were scored as the sum of vaccine-
related responses, achieving an immunological score ranging 
0 to 6 (three tests by two time-points): the immunological 
success was defined as the achievement of an immunologi-
cal score ≥ 3.
Analysis of vaccine‑specific IFNγ + T cell frequency 
by intracellular staining and flow cytometry
The frequencies of IFNγ-secreting CD8 + and CD8- T cells 
after incubation with the vaccination peptides were evalu-
ated by intracytoplasmic immunofluorescence analyses, 
as follows. Peripheral blood mononuclear cells (PBMC) 
(1 ×  106 cells), obtained from heparinized peripheral blood 
by centrifugation on Ficoll gradient and re-suspended in 
RPMI conditioned by 10% AB serum, were stimulated over-
night at 37 °C by a mix of the four GX301 vaccine peptides 
(5 µg/ml each) in presence of purified anti-human CD28 
(clone CD28.2) and anti-CD49d (clone L25) mAbs both at 
1 µg/ml concentration (BD). Brefeldine A (BFA, Sigma) 
(10 µg/ml) was added to samples for the last four hours of 
incubation. Samples cultured without peptides or stimulated 
with PMA and ionomycin (Sigma) were considered negative 
and positive controls, respectively.
Then, washed samples were incubated with vitality dye 
LIVEDEAD (Molecular Probes, Thermo Fisher) before pro-
ceeding with surface staining. The following fluorochrome-
conjugated mAbs were used: PE-conjugated anti-human 
CD8 clone SK1, APC-conjugated anti-human CD3 clone 
UCHT1 (BD). After surface staining, Cytofix/Cytoperm 
kit (BD) was used to fix and permeabilize the lymphocytes 
following the manufacturer’s instructions. The cells were 
washed in Perm-Wash buffer (BD) and incubated with a 
FITC-conjugated anti-human IFNγ mAb (BD). There-
after, the samples were washed in Perm-Wash buffer, re-
suspended in FACS Lysing solution (BD) and analysed by 
a LSR Fortessa X20 flow cytometer (BD) using the FACS 
DIVA software (BD) v8.1.0. The results were expressed as 
frequency of IFN-γ producing cells in CD3 + CD8 + or in 
CD3 + CD8- alive lymphocytes after subtracting the fre-
quency of unstimulated T cells spontaneously producing 
IFNγ cytokine.
Positive responses were considered those either absent at 
baseline or greater than twice the baseline showing ≥ 0.1% 
background positive cells, as suggested for low frequency 
reactivity [33].
ELISPOT analyses
In order to detect IFNγ-producing T cells reactive against 
the GX301 peptides, ELISPOT analyses were performed on 
freshly isolated PBMC using the Human IFNγ ELISPOT 
Kit according to the manufacturer’s instructions (BD) and 
following the indications of international proficiency pan-
els [34]. Briefly, PBMC (2 ×  105 cells in X-VIVO medium, 
Euroclone) were incubated overnight with a mix of the four 
GX301 vaccine peptides (5 µg/ml each) in the presence of 
anti-human CD28 and anti-human CD49d mAbs (BD) (both 
at 1 µg/ml), or with phytohaemagglutinin (PHA-P, MPBIO) 
at 1 mg/ml, as positive control, or medium alone as negative 
controls.
Positive responses were considered those either absent 
at baseline or greater than twice the baseline showing ≥ 10 
spots and ≥ 2 × background spot number.
Cytotoxic assay
Vaccine-specific cytotoxic activity of circulating T lym-
phocytes was analysed by flow cytometry, as follows [35]. 
PBMC (10 ×  106) were re-suspended in 1 ml of PBS con-
taining CFDA-SE 5 µM (Molecular Probes, Thermo Fisher) 
for 5 min at room temperature and then washed twice in 
PBS-1% AB serum at 4 °C. Monocytes were positively 
sorted from labelled-PBMC by CD14 Micro-Beads human 
Kit according to the manufacturer’s instructions (Miltenyi) 
and pulsed or not (1 ×  105/well) overnight with a mix of the 
four GX301 vaccine peptides (5 µg/ml each). The day after, 
PBMC (2 ×  106/ml) were incubated for 6 h at 37 °C with 
1 ×  105 CFDA-SE-labelled, pulsed or un-pulsed, autologous 
monocytes as target cells. Thereafter, cells were washed with 
PBS and re-suspended in 300 µl of PBS added with 5 µl 
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of 7-AAD (BD) before flow cytometer analysis. The sam-
ples were analysed by a FACSCanto II flow cytometer (BD) 
using FACS DIVA software (BD) v 6.1.3.
The percentage of specific lysis was calculated as
Achieved values were normalized for the percentage 
of CD3 + CD8 + T cells detected among PBMC. Positive 
responses were considered those either absent at base-
line or greater than twice the baseline showing ≥ 15% of 
specific lysis.
Immune phenotyping of peripheral lymphocytes 
subpopulations
Immune phenotyping of peripheral blood lymphocytes 
was performed as follows. One hundred µl of washed 
whole blood, collected in Vacutainers containing tet-
rasodium EDTA, were incubated with pre-mixed, pre-
optimized, multicolour ‘cocktails’ of antibodies within 
12 × 75 mm flow cytometry tubes (Lyotube, Becton Dick-
inson, BD) for 30 min at 4 °C. The cocktails were opti-
mized in two panels to evaluate the frequency of T, B, NK 
cell subpopulations, CD8 + and CD4 + T regulatory (Treg) 
cells, CD8 + and CD4 + T cell maturation and activation. 
The first panel included the following fluorochrome-
conjugated monoclonal antibodies (mAbs): BD Horizon 
V450 (V450)-conjugated anti-human HLA-DR clone 
L243(G46-6), BD Horizon V450 (V500)-conjugated anti-
human CD45 clone 2D1, fluorescein(FITC)-conjugated 
anti-human CD3 clone UCHT1, allophycocyanin(APC)-
conjugated anti-human CD8 clone SK1, APC-H7-conju-
gated anti-human CD4 clone SK3, phycoerythrin(PE)-
conjugated anti-human CD16 + CD56 + clones B73.1 
and MY31, PE-Cyanin7(PE-Cy7)-conjugated anti-human 
CD19 clone SJ25C1. The second panel included the fol-
lowing fluorochrome-conjugated mAbs: V450-conjugated 
anti-human CD45RA clone HI100, V500-conjugated 
anti-human CD3 clone UCHT1, Brilliant violet(BV)711-
conjugated anti-human CD8 clone SK1, FITC-conjugated 
anti-human CD127 clone HIL-7R-M21, peridinin-chlo-
rophyll proteins(PerCP)-Cy5.5-conjugated anti-human 
CCR7 clone 150503, APC-conjugated anti-human CD39 
clone TU66, APC-H7-conjugated anti-human CD4 clone 
SK3, PE-conjugated anti-human CD28 clone CD28.2, 
PE-Cy7-conjugated anti-human CD25 clone 2A3. Cells 
were then re-suspended in 100 µl of PBS and 10 µl of 
7-AminoactinomycinD (7-AAD, BD) were added as 


















viability staining solution to exclude dead cells. Samples 
were analysed by a LSR Fortessa X20 flow cytometer 
(BD) using the FACS DIVA software (BD) v8.1.0.
Clinical efficacy assessment
Progression-free survival (PFS) and overall survival (OS) 
were secondary end-points. Assessment of clinical efficacy 
was based on the evaluation of serum PSA time-course 
and on the evaluation of disease evolution through clinical 
examination and imaging analyses repeated at fixed time 
intervals or at any time if deemed necessary by the local 
investigators.
Sample size and statistical analyses
Sample size was estimated under the assumption of the fol-
lowing immunological success rates: regimen A,  ≥ 90%; 
regimen B, 60–70%; regimen C, ≤ 45%. A sample size of 
40 patients per group (total n. = 120) had 75% to 99% statis-
tical power to detect the expected differences at both steps of 
comparison. To compare frequency distribution of variables, 
contingency analyses were performed by Fisher’s exact test.
PFS and OS were estimated with the Kaplan–Meier 
method. Data of patients who were lost to on-study obser-
vation or follow-up were censored at the time of the last 
available information. GX301 regimens were compared for 
PFS and OS using the log-rank test. Association of selected 
putative prognostic factors (i.e. time to CRPC diagnosis, 
class of cumulative docetaxel dose and outcome of docetaxel 
chemotherapy) with PFS or OS was investigated with Cox 
regression model. All patients who received at least one 
GX301 administration were included in the analyses.
Results
Patient features, number and distribution 
among the three treatment regimens
Ninety-nine patients were enrolled in the study. One of them 
withdrew spontaneously: the remaining 98 were randomized 
into the three regimen groups for receiving either eight (regi-
men 1, n = 32), four (regimen 2, n = 33) or two (regimen 
3, n = 33) vaccine administrations, respectively. All the 98 
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randomized patients received the vaccine accordingly to 
the assigned schedule: however, among them, only 63 were 
assessable for immunological efficacy based on protocol cri-
teria, due to withdrawn from observation before the 180-day 
time-point of 25 patients.
Baseline patient characteristics are summarized in 
Table 1.
Safety assessment
Safety was analysed in all 98 patients who received at least 
one vaccine administration. Among AEs, panniculitis-like 
local inflammation at the site of vaccine administration was 
common to all patients. The frequency of inflammatory reac-
tion at injection sites increased, as expected, with the num-
ber of vaccine administrations. Overall, SAEs were rare and 
mostly unrelated to GX301 vaccination. In particular, only 
one fatal event was registered due to the onset of a second 
neoplasia (glioblastoma multiforme). Table 2 summarizes 
Table 1  Baseline patient features
*Mean (SD); **Median (range)
Regimen 1 (n = 32) Regimen 2 (n = 33) Regimen 3 (n = 33) All regimens (n = 98)
Age (years)* 68.7 (9.8) 70.8 (7.6) 68.3 (8.6) 69.3 (8.7)
Body mass index* 28.1 (5.3) 27.8 (3.0) 28.8 (5.2) 28.2 (4.6)
HLA-A2 + haplotype (n.) 11 10 7 28
Time since first PC diagnosis (years)* 5.0 (4.8) 6.8 (5.6) 4.6 (4.5) 5.5 (5.0)
Gleason score** 8.0 (6–10) 8.0 (6–10) 8.0 (6–9) 8.0 (6–10)
Time since CRPC diagnosis (months)* 12.9 (7.4) 13.1 (7.9) 15.0 (10.2) 13.7 (8.6)
Pre-docetaxel abiraterone or enzalutamide (n.) 3 4 2 9 (9.2%)
Cumulative docetaxel dose
 300–525 mg/m2 (n.) 10 10 13 33 (33.7%)
 526–825 mg/m2 (n.) 21 21 20 62 (63.3%)
  > 825 mg/m2 (n.) 1 2 0 3 (3.1%)
Time since last docetaxel infusion (weeks)* 10.8 (5.9) 12.5 (9.1) 12.8 (17.2) 12.1 (11.7)
Docetaxel outcome
 Response (n.) 26 20 30 76 (77.6%)
 Disease stability (n.) 6 13 3 22 (22.4%)
Metastatic sites
 Skeletal only (n.) 8 13 13 34 (34.7%)
 Soft tissue (nodal, visceral) only (n.) 6 5 5 16 (16.3%)
 Bone and soft tissue (n.) 18 14 15 47 (48.0%)
Serum testosterone < 1.7 nmol/L (n.) 30 33 33 96 (98.0%)
ECOG performance status 0/1 (n.) 24/8 24/9 20/13 68/30
Table 2  Summary of non-fatal 
treatment-emergent SAEs
SAE type Regimen 1 n. (%) Regimen 2 n. (%) Regimen 
3 n. (%)
Loss of consciousness 1 (3)




Systemic inflammatory syndrome 1 (3)
Infections 1 (3)
Neoplasm (bladder cancer) 1 (3)
Total subjects with non-fatal treatment-
emergent SAEs
2 (6.3) 2 (6.1) 1 (3)
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serious non-fatal adverse events: a total of eight SAEs was 
observed in two, two and one patients in regimen 1, regimen 
2 and regimen 3, respectively.
Importantly, no events relative to induction of severe lympho-
penia after vaccination were registered in our series (not shown).
Moreover, no onset of autoimmunity-related clinical signs 
or of autoantibodies was observed.
Immunological response
Sixty-three patients were assessable for the immunological 
outcome (n = 20, n = 24 and n = 19 for regimen 1, regimen 
Fig. 1  Representative examples of performed immunological analy-
ses. a ELISPOT assays performed after 180  days from vaccination 
on PBMC from patient #16 (low response, upper panels) and after 
90 days from vaccination on PBMC from patient #67 (high response, 
lower panels); b intracellular cytokine staining of CD8-IFNγ + and 
CD8 + IFNγ + circulating T cells specific for GX301 peptides after 
180 days from vaccination in blood sample derived from patient #51 
(low response, upper panels) and after 90  days from vaccination in 
blood sample derived from patient #32 (high response, lower pan-
els); c GX301 peptides specific cytotoxicity assays performed after 
90 days from the first immunization with PBMC of patient #35 (low 
response, upper panels) and patient #72 (high response, lower panels) 
against autologous monocytes pulsed (right panels) or not (left pan-
els) with the four GX301 peptides
Table 3  Immunological score and responder rate among assessable GX301 treated patients
*The immunological score was the sum of positive responses observed at the immunological tests performed on days 90 and 180 after vaccina-
tion
**As per protocol criteria, immunological responders were patients achieving an immunological score ≥ 3
Immunological score* (n.) Regimen 1 (n = 20) Regimen 2 (n = 24) Regimen 3 (n = 19) All regimens (n = 63)
0 0 0 3 3 (4.8%)
1 4 3 4 11 (17.5%)
2 3 8 4 15 (23.8%)
3 12 11 4 27 (42.9%)
4 1 1 4 6 (9.5%)
5 0 1 0 1 (1.6%)
6 0 0 0 0
Immunological responders** 
(score ≥ 3), n. (%)
13 (65) 13 (54.2) 8 (42.1) 34 (54.0)
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2 and regimen 3, respectively). Representative analyses 
for each type of immunological tests are shown in Fig. 1.
Sixty out of 63 (95%) immunized patients who com-
pleted the vaccination protocol showed at least one positive 
response at one of the tests performed on days 90 and 180 
after the first immunization. The only three patients who did 
not show any vaccine-specific immune response belonged to 
the regimen 3 (Table 3).
Responders to vaccination, as per protocol criteria, ranged 
from 42 to 65% of patients with a proportional relationship 
between rates of immunological responders and number of 
immunizations administered by each regimen (Table 3).
Since one of the four immunogenic peptides 
 (hTERT540–548) included in the GX301 vaccine is restricted 
by the HLA-A2 allele, we compared the responder rates 
between the HLA-A2 positive and negative patients and no 
differences were observed (not shown).
Interestingly, taking into consideration the total number 
of positive and negative responses to the six immunologi-
cal tests performed at days 90 and 180 in either the total 
patient population receiving the vaccine (n. 98 patients) 
or the immunological assessable patient population (63 
patients), the comparison of the rates of positive responses 
at any of the six immunological tests among the different 
regimens showed a significant difference between regimen 2 
and regimen 3, while no differences were observed between 
either regimen 1 and regimen 3 or regimen 1 and regimen 
2 (Fig. 2).
Fig. 2  Comparison of response rates among the different regimens. 
Contingency analyses comparing the number of positive and negative 
immunological responses between either regimen 1 and regimen 2 (a 
and d), regimen 1 and regimen 3 (b and e), or regimen 2 and regimen 
3 (c and f) among either the overall 98 patient series (a–c) or the 63 
patients assessable for the immunological outcome (d–f). Concern-
ing the overall 98 patient series (a–c), the total numbers of performed 
tests were 117, 144 and 114 for regimens 1, 2 and 3, respectively; 
concerning the group of 63 patients assessable for the immunological 
outcome (d–f), the total numbers of performed tests were 147, 172 
and 150 for regimens 1, 2 and 3, respectively
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Analyses of T cell subpopulations
The circulating frequencies and absolute numbers of dif-
ferent T cell subsets were assessed at baseline and after 
90 and 180 days from baseline. T cell subsets to be ana-
lysed were selected for (a) maturation stage, in terms 
of CCR7 + CD45RA + naïve, CCR7 + CD45RA- cen-
tral memory (CM), CCR7 + CD45RA- effector mem-
ory (EM), and CCR7 + CD45RA + terminal effector 
memory cells (TEM), and b) regulatory commitment, in 
terms of both CD4 + CD127-CD25hi and CD8 + CD28-
CD127loCD39 + Treg, respectively.
The comparison of circulating T cell subset frequencies 
or absolute numbers between immunologically responder 
and non-responder patients showed that at baseline the only 
difference concerned the frequency of naïve CD8 + T cells, 
that was lower in responders than in non-responder patients 
(Fig. 3a).
In order to have a picture on the dynamics of T cell subset 
frequencies and absolute numbers upon GX301 vaccination, 
the differences (Δ) were calculated between values at day 90 
or at day 180 and values at baseline; then, such differences 
were compared between responders and non-responders. 
This analysis showed that responders had a significantly 
higher increase in absolute number of circulating CD4 + T 
cells at day 180 than non-responders (Fig. 3b).
Clinical outcome
Fifty per cent of patients underwent disease progression 
within day 163 and 75% within day 183 (Fig. 4a), with no 
statistically significant or trend differences among GX301 
regimens (Fig. 4b).
Post-study follow-up was completed by 95% of patients. 
OS was 62% at 18 months and 48% at 24 months (Fig. 4c) 
with no statistically significant differences among GX301 
regimens (Fig. 4d).
In order to have a rough estimate of clinical efficacy of the 
vaccine, the analysis of survival following disease progres-
sion was calculated for patients with documented disease 
progression (n = 82 out of 98 enrolled patients). Median 
survival of patients progressing after vaccine administra-
tion was 17.3 months (Fig. 5a). This value increases to 
19.9 months limiting the analysis to the 59 patients who 
were treated at progression with either abiraterone acetate, 
enzalutamide or cabazitaxel (used alone or in sequential 
combinations) (Fig. 5b).
Relationship between immunological parameters 
and clinical outcome
In order to investigate on the possible association between 
immunological response to GX301 vaccine and clinical out-
come, PFS and OS were compared between responders and 
non-responders, irrespective of the assigned regimen. Fig-
ure 6a, b shows that no significant differences were observed 
between the two groups.
Then, we wondered whether the level or dynamics of 
some T cell subsets could be predictive of clinical out-
come. Hence, we found that baseline absolute number of 
CD4 + Treg impacted on PFS since patients with baseline 
number < 30.3 CD4 + Treg/μl had a lower risk of progres-
sion than patients with baseline number > 30.3 CD4 + Treg/
μl (Fig. 7a). Concerning OS, we observed that patients who 
had a day 180 vs baseline Δ < 37.2 of CD3 + T cell number/
μl and < − 0.4 of CD8 + T cell percentage had a more pro-
longed survival than patients with Δ values > 37.2 CD3 + T 
cell number/μl and > − 0.4 CD8 + T cell percentage, respec-
tively (Fig. 7b, c).
Fig. 3  Comparisons of T cell subset frequency or number between 
immunologically responder and non-responder patients relative to: a 
comparison between immunologically responder and non-responder 
patients relative to the frequency of naïve CD8 + T cells at baseline; b 
comparisons between immunologically responder and non-responder 
patients concerning the differences between day 90 or day 180 val-
ues and baseline relative to the absolute number of circulating CD4 
T cells
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Interestingly, a decreased number at day 180 of 
CD8 + Treg (identified as shown in Supplementary Fig. 1) 
was associated with a better prognosis (Fig. 7d), a phenom-
enon non-dependent on the trend of the non-Treg CD8 + T 
cell subpopulation (Fig. 7e).
Discussion
How the regimen of a cancer vaccine may impact on its effi-
cacy? High number of administrations may have a bi-faceted 
effect, either boosting the immunization or exhausting the 
memory immune response [32]. Hence, this trial was specifi-
cally designed to comparatively analyse, other than safety, 
the immunological response to three different GX301 cancer 
vaccine schedules in a cohort of mCRPC patients.
GX301 vaccination proved to be remarkably safe at 
all tested regimens. No serious or Grade ≥ 3 AEs were 
considered to be treatment-related. Laboratory tests aimed 
at detecting possible autoimmune reactions yielded essen-
tially negative findings. The most represented AE was the 
skin inflammatory reaction at GX301 injection sites often 
associated with flu-like systemic symptoms.
Concerning the immunological outcomes, GX301 proved 
to be effective in inducing some immunological response 
in 95% of patients (100% with the more intense regimens). 
Moreover, immunological success, as per protocol crite-
ria, was achieved by 65% of patients with the most intense 
regimen. These results, confirming in a wider series those 
achieved in a previous small phase I trial [31], support that 
immune tolerance does not remarkably affect responses 
against telomerase, although it is an endogenous antigen. 
This is not surprising since telomerase is stably expressed 
only during the foetal life, at a time when the immune sys-
tem is not mature yet. After birth, cells repress the telom-
erase gene, which is only fleetingly expressed by stem cells 
Fig. 4  Progression-free survival and overall survival in the overall 
study population or according to GX301 regimens. a Progression-free 
survival in the overall study population. Number of censored cases 
before the end of observation: 16; number of progressions by day 
540: 82; time to progression: 163 days (IQR: 95–183); estimated Pro-
gression-free survival: 77.3% at day 90, 29.5% at day 180, 10.7% at 
day 270. b Progression-free survival according to GX301 regimens. 
Median times to progression (IQR) for regimen 1, regimen 2 and reg-
imen 3 were, respectively, 150 days (102–179), 176 days (105–187) 
and 128 days (88–181). c Overall survival in the overall study popu-
lation. Number of censored cases before the end of observation: 49; 
number of deaths by day 720: 49; median time to death (IQR): 698 
(452-not reached); estimated survival: 99% at day 180, 84% at day 
360, 62% at day 540, 48% at day 720. d Overall survival according 
to GX301 regimens. Numbers of deaths by day 720 were for regi-
men 1, regimen 2 and regimen 3 were 16, 14 and 19, respectively; 
median times to death (IQR) for regimen 1, regimen 2 and regimen 
3 were, respectively, 698 (367-not reached), not determined (503-not 
reached), 654 (474-not reached)
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or by actively replicating cells [36]. Hence, when tumour 
cells appear in the organism and constitutively re-express 
telomerase, T lymphocytes recognize it as a new antigen and 
mount a specific immune response, a capacity shared by the 
immune T cells of both cancer patients and healthy subjects 
(30). Interestingly, immunological responders showed lower 
frequency of naïve CD8 + T cells at baseline and higher 
number of CD4 + T cells at day 180 from vaccination than 
non-responders. These findings imply that a pre-vaccination 
increased repertoire of effector/effector memory CD8 + T 
lymphocytes and achievement upon vaccination of a robust 
CD4 + T cell response are essential requirements for an 
effective anti-cancer vaccination.
The weaknesses of this study are the actual sample size 
of treated patients (n = 98) fell short of the planned one 
(n = 120) and that the immunological outcomes could not 
be assessed in 35 patients, so that the assessable sample was 
reduced to 63 patients: hence, between-regimen differences 
in responder rates were smaller than assumed in the proto-
col estimation of the sample size, not reaching conventional 
statistical significance. Notwithstanding this fact, the results 
indicate a superiority of the 8- and 4-administration regi-
mens over the 2-administration scheme suggesting that for 
GX301 cancer vaccine, repeated administrations are neces-
sary for inducing effective immunization. Interestingly, part 
of the detected responses was long-lasting (6 months after 
the first vaccine administration) suggesting the capacity of 
GX301 vaccine to induce memory T cell responses.
In the present study, PFS and OS did not appear to be 
related to immunological outcomes. However, the trial was 
Fig. 5  Overall survival in 
patients with documented 
disease progression. a Overall 
survival in 82 patients with 
documented disease progres-
sion treated with GX301 
vaccine. b Overall survival in 
59 patients with documented 
disease progression treated 
with GX301 vaccine and then 
with either abiraterone acetate, 
enzalutamide, or cabazitaxel 
(used singularly or in sequential 
combination)
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not powered to detect differences between vaccination regi-
mens in PFS or OS. In order to have indications on the clini-
cal efficacy of GX301 vaccine, we calculated the median OS 
from progression in all patients with documented progres-
sion (17.3 months), as well as in patients with documented 
progression treated thereafter with either abiraterone acetate, 
enzalutamide and cabazitaxel (19.9 months). Interestingly, 
these OS values were non-inferior to those of patients fail-
ing after front-line docetaxel, that were reported to be 15.8, 
18.4 and 15.1 months after treatment with abiraterone ace-
tate [5], enzalutamide [6], or cabazitaxel [4], respectively. 
These findings are not sufficient per se to suggest a benefi-
cial effect of the vaccination on patients survival; however, 
they allow to rule out any putative detrimental effect in this 
regard. Moreover, the immune efficacy shown by GX301 in 
our study rules out that previous docetaxel treatment might 
have blunted the immunological response to the vaccine, 
confirming the data of other recent reports [37–42].
Interesting insights came from the evaluation of the dynam-
ics of circulating Treg subsets. We observed that PFS after 
GX301 vaccination was inversely dependent on the frequency 
of CD4 + Treg at baseline, reminiscent of what already observed 
in experimental animal models [43]. Moreover, the circulating 
number of CD8 + CD28-CD127-CD39 + Treg, a CD8 + Treg 
subset that heavily infiltrates human cancer [44, 45], showed a 
highly significant predicting value since reduced (with respect 
Fig. 6  Progression-free survival 
(a) and overall survival (bb) 
in immunologically responder 
vs non-responder patients. a 
Median time to progression for 
responder and non-responder 
patients were 174 days and 
182 days, respectively; b 
Median time to death was not 
reached in either group
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to baseline) levels of these cells at 180 days after GX301 vacci-
nation predisposed patients to a prolonged survival. The setting 
of our study cannot permit to differentiate whether the predict-
ing value of circulating CD8 + CD28-CD127-CD39 + Treg 
number relates to the effects of the vaccination or to the chem-
otherapy (or to their combination). However, these findings, 
suggesting a shift from effector to regulatory T cell functions, 
support the opportunity to constitutively associate cancer vac-
cines with the administration of agents able to counteract Treg 
activity (i.e. specific immune checkpoint blockers).
Conclusions
The results of our study show that (a) GX301 cancer vaccine 
is substantially safe and immunogenic; (b) higher numbers 
of administrations provide a better immunological response 
than lower numbers; (c) the median OS from disease pro-
gression is promising enough to suggest the opportunity to 
further testing GX301 in m CRPC; (d) the dynamics in the 
circulation of specific T cell subsets, in particular of Treg, 
may have a prognostic value. This latter point, providing a 
possible mechanism explaining the poor efficacy of cancer 
vaccines, except sipuleucel, in PC, opens a perspective for 
Fig. 7  Progression-free survival (a) and Overall survival according to 
the level or dynamics of different T cell subsets. a Progression-free 
survival according to the circulating absolute number of CD4 + Treg 
at baseline; b Overall survival according to a 180 days versus base-
line Δ of circulating CD3 + T cell number/μl ≤ (blue line) or > (red 
line) 37.2; c Overall survival according to a 180  days versus base-
line Δ of circulating CD8 + T cell frequency ≤ (blue line) or > (red 
line) − 0.4; d Overall survival according to a 180 days versus base-
line Δ of circulating CD8 + Treg number/μl decreased (blue line) or 
not-decreased (red line); e Overall survival according to a 180 days 
versus baseline Δ of circulating CD8 + non-Treg number/μl decreased 
(blue line) or not-decreased (red line)
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the combination of GX301, administered with a four or eight 
administration schedules, with immune-check point inhibi-
tors in the treatment of PC.
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